Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ½ÃÀ庸°í¼­ > ÆÄ¸Ó½´Æ¼Äà > ½Å°æÁúȯ > ¼¼°èÀÇ ÁßÃ߽Űæ°è(CNS) Ä¡·áÁ¦ ½ÃÀå : ÁÖ¿ä °ø±Þ¾÷ü Æò°¡
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4920)
°¨¿°Áúȯ (349)
°ñÁúȯ Ä¡·á (38)
´ç´¢º´ (194)
¹é½Å (180)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (44)
ºñó¹æ ÀǾàǰ (152)
¼öÀÇÇÐ (17)
½Å°æÁúȯ (174)
½Å¾à°³¹ß (1520)
¾ÏÄ¡·á (941)
¾à¹°Àü´Þ (185)
ÀǾàǰ ±ÔÁ¦È¯°æ (127)
Á¤½ÅÁúȯ (85)
Á¦³×¸¯ ÀǾàǰ (128)
Á¦¾àȸ»çºÐ¼® (522)
󹿾à (165)
½ÃÀ庸°í¼­

¼¼°èÀÇ ÁßÃ߽Űæ°è(CNS) Ä¡·áÁ¦ ½ÃÀå : ÁÖ¿ä °ø±Þ¾÷ü Æò°¡

Global CNS Drug Market: Strategic Assessments of Leading Suppliers

¸®¼­Ä¡»ç Venture Planning Group
¹ßÇàÀÏ 2011³â 09¿ù »óǰÄÚµå 216709
ÆäÀÌÁö Á¤º¸
°¡°Ý
US $ 9,800 £Ü 11,657,100 PDF by E-mail (Local license)
US $ 19,400 £Ü 23,076,300 PDF by E-mail (Global license)


Venture Planning Group ¿¡¼­ 2011³â 09¿ù ¿¡ ¹ßÇàÇÑ ¡¸¼¼°èÀÇ ÁßÃ߽Űæ°è(CNS) Ä¡·áÁ¦ ½ÃÀå : ÁÖ¿ä °ø±Þ¾÷ü Æò°¡¡¹ º¸°í¼­´Â US $9,800 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ÁßÃ߽Űæ°è(CNS) Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä °ø±Þ¾÷ü¿¡ ´ëÇØ ½ÇÀû, ´É·Â, ¸ñÇ¥, Àü·«, Ä«Å×°í¸®º°, Áö¿ªº° ¸ÅÃâ ¿¹Ãø µî Æ÷°ýÀû Á¤º¸¸¦ Á¦°øÇϰí, °ø±Þ¾÷ü, ÇâÈÄ ½ÃÀå ÁøÃâÀ» °í·ÁÇϰí ÀÖ´Â ±â¾÷, °æÀï»ç µîÀ» Áö¿øÇϱâ À§ÇÑ ÆÇ¸Å, Á¦ÈÞ¿Í Àμö, ¸¶ÄÉÆÃ, R&D Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

    ¸ñÂ÷
    • Abbott
      • °³¿ä
      • ¼ÒÀ¯±Ç
      • »ç¾÷ Àü°³
      • Á¶Á÷°ú °ü¸®
      • ÁÖ¿ä ½Ã¼³
      • Á¦Ç° Æ÷Æ®Æú¸®¿À ¹× ±â¼úÀû ³ëÇÏ¿ì
      • ¸¶ÄÉÆÃ ´É·Â
      • À繫 ºÐ¼®
      • °­Á¡°ú ¾àÁ¡
      • Àü·«ÀÇ ¹æÇ⼺
    • AstraZeneca
    • Bristol-Myers Squibb
    • Eli Lilly
    • GlaxoSmithKline
    • Johnson & Johnson
    • Merck
    • Novartis
    • Pfizer
    • Roche
    • Sanofi-Aventis
    • Wyeth
    µµÇ¥
LSH
Back to Top